Drug Trial Radar · NCT00809965
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15,526
Actual
Start
Nov 2008
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Dec 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.
Conditions
- Acute Coronary Syndrome
- Myocardial Infarction
- Myocardial Ischemia
- Unstable Angina
Interventions
Rivaroxaban 2.5 mgDrug
One tablet twice daily
Rivaroxaban 5 mgDrug
One tablet twice daily
PlaceboDrug
One placebo tablet twice daily
Standard of careDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or StrokeTime frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
Locations
556 sites in 43 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Geneva, Alabama
Site not named
Mobile, Alabama
Site not named
Anaheim, California
Site not named
Burbank, California
Site not named
Los Angeles, California
Site not named
Mission Hills, California
Site not named
San Diego, California
Site not named
Aurora, Colorado
Site not named
Littleton, Colorado
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Kissimmee, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Ormond Beach, Florida
Site not named
St. Petersburg, Florida
Site not named
Columbus, Georgia
Site not named
Rome, Georgia
Site not named
Aurora, Illinois
Site not named
Indianapolis, Indiana
Site not named
Merrillville, Indiana
Site not named
Munster, Indiana
Site not named
Valparaiso, Indiana
Site not named
Overland Park, Kansas
Site not named
Wichita, Kansas
Site not named
Lacombe, Louisiana
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
Flint, Michigan
Site not named
Grand Blanc, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Kalamazoo, Michigan
Site not named
Mount Clemens, Michigan
Site not named
Petoskey, Michigan
Site not named
Tupelo, Mississippi
Site not named
St Louis, Missouri
Site not named
Kalispell, Montana
Site not named
Bridgewater, New Jersey
Showing 40 of 556 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.